{
  "id": 171497,
  "title": "Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map",
  "url": "https://urgent.news/2026/08/05/recursion-partners-with-genentech-to-advance-first-validated-neuro",
  "topic": "ai",
  "section": "AI",
  "published": "2026-08-05T10:30:48.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/artificial-intelligence/recursion-partners-with-genentech-to-advance-first-validated-neuro-target-discovered-through-ai-map/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map. The 4.5 year, up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion and Genentech to co-develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they created to find new targets in a long-challenging therapeutic area. Genentech has exercised the collaboration’s first validated target option after accepting from Recursion a validation package for the target. That acceptance will trigger a $3 million milestone payment from the biopharma giants to Recursion. That latest payment raises to $216 million the total cash paid out by the biopharma giants to Recursion since the AI-based drug developer joined with the pharma giant and its subsidiary to launch their partnership in 2021.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}